OncoMatch/Clinical Trials/NCT04998669
Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma
Is NCT04998669 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Loncastuximab tesirine and Rituximab for follicular lymphoma.
Treatment: Loncastuximab tesirine · Rituximab — The purpose of this research is to see if Loncastuximab Tesirine in combination with Rituximab will result in higher complete response rate when given to treat follicular lymphoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD19 expression (positive)
Participants who have received previous CD19-directed therapy must have a biopsy which shows CD19 expression after completion of the CD19-directed therapy.
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic therapy
relapsed or refractory FL previously treated with ≥1 line of systemic therapy
Cannot have received: systemic immunochemotherapy
≥ 6 lines of systemic immunochemotherapy for treatment of FL
Lab requirements
Blood counts
Absolute neutrophil count ≥1000/mm3 (unless due to lymphoma involvement of the bone marrow or spleen). Platelets ≥100,000/mm3 or ≥ 60,000/mm3 in case of bone marrow involvement by lymphoma. Hemoglobin ≥ 10 g/dL or ≥8 g/dL in case of bone marrow involvement by lymphoma.
Kidney function
Creatinine within normal institutional limits, or creatinine clearance ≥30 ml/min/1.7m^2 for patients with creatinine levels above institutional normal (unless due to lymphoma).
Liver function
Total bilirubin < 1.5 x within normal institutional limits (unless due to lymphoma involvement of liver or a known history of Gilbert's disease). GGT/AST/ALT ≤ 2.5 × institutional upper limit of normal.
Patients must have normal organ and marrow function as defined below...
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Florida Cancer Specialists and Research Institute · Fort Myers, Florida
- University of Miami · Miami, Florida
- University of Michigan · Ann Arbor, Michigan
- Rutgers Cancer Institute of New Jersey · New Brunswick, New Jersey
- Allegheny Health Network · Pittsburgh, Pennsylvania
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify